SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Sana Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.30+0.03 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $680.03M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.73 (−54.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $680.03M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.40
- Dividend yield
- –
- Free cash flow yield
- -19.86%
Fundamentals
- Net income
- -$211.82M
- EPS, diluted
- -$0.76
- Free cash flow
- -$135.06M
- Book value per share
- $0.52
- Diluted shares
- 296M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$218.75M
Net income
-$211.82M
EPS, diluted
-$0.76
Free cash flow
-$135.06M
Reported periodTrailing twelve months